The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 25, 2018

Filed:

May. 05, 2015
Applicant:

Baylor College of Medicine, Houston, TX (US);

Inventors:

Bert W. O'Malley, Houston, TX (US);

Subhamoy Dasgupta, Houston, TX (US);

Nicholas Mitsiades, Boston, MA (US);

Arun Sreekumar, Sugar Land, TX (US);

Sean E. Mcguire, Bellaire, TX (US);

Assignee:

Baylor College of Medicine, Houston, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/60 (2006.01); G01N 33/00 (2006.01); G01N 33/48 (2006.01); G01N 33/574 (2006.01); A61K 31/585 (2006.01); A61K 38/24 (2006.01); C12Q 1/16 (2006.01); G21H 5/02 (2006.01); A61K 31/198 (2006.01);
U.S. Cl.
CPC ...
G01N 33/60 (2013.01); A61K 31/198 (2013.01); A61K 31/585 (2013.01); A61K 38/24 (2013.01); C12Q 1/16 (2013.01); G01N 33/00 (2013.01); G01N 33/48 (2013.01); G01N 33/574 (2013.01); G01N 33/57434 (2013.01); G21H 5/02 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01);
Abstract

Embodiments of the disclosure include methods and compositions for treatment of prostate cancer, including metastatic prostate cancer or prostate cancer at risk for developing into metastatic prostate cancer, by providing an effective therapy to an individual that has been determined to have elevated levels of SRC-2 (also known as NCOA2, GRIP1 TIF2). In particular cases, sample from an individual known to have prostate cancer is assayed for the risk for developing metastatic prostate cancer and the individual is provided an effective therapy upon determination of elevated levels of SRC-2.


Find Patent Forward Citations

Loading…